FGP
AMRX icon

Freestone Grove Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Freestone Grove Partners’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-72,844
Closed -$905K – 1011
2026
Q1 		$905K Buy
+72,844
New +$978K 0.01% 500

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Freestone Grove Partners's AMRX Position: Q2 2026 in Review

Freestone Grove Partners sold out of Amneal Pharmaceuticals (AMRX) in Q2 2026, closing a stake of 72,844 shares — an estimated $905K sold.

Freestone Grove Partners first reported a position in AMRX in Q1 2026 and held it in 1 quarter. The position peaked at $905K in Q1 2026. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Freestone Grove Partners reported no remaining Amneal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 72,844 Amneal Pharmaceuticals shares in Q2 2026, an estimated $905K.
  • Freestone Grove Partners first reported a position in Amneal Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Amneal Pharmaceuticals position peaked at $905K in Q1 2026.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.